ELIQUIS (apixaban) dosing for patients with DVT / PE

The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding.¹

ELIQUIS indications1	Dose1	Morning*	Night*
DVT / PE treatment: treatment of DVT and PE in adults	Day 1–7: 10 mg BD	ELIQUIS 5 mg x2	ELIQUIS 5 mg x2
	Day 8 onwards: 5 mg BD for at least 3 months Short duration of treatment (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation).1	ELIQUIS 5 mg	ELIQUIS 5 mg
Prevention of recurrent DVT / PE: prevention of recurrent DVT and / or PE in adults following completion of 6 months of treatment with ELIQUIS 5 mg BD or with another anticoagulant treatment for DVT or PE	2.5 mg BD	ELIQUIS 2.5 mg	ELIQUIS 2.5 mg

* Tablets shown are not actual size.

• Eliquis is not recommended in patients with CrCl <15ml/min or in patients undergoing dialysis
• The use of Eliquis is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp. For the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT/PE, Eliquis should be used with caution in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp. For the treatment of DVT /PE, in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp, Eliquis should not be used since efficacy may be compromised. See SmPC for complete information on drug-drug interactions.